Significantly more patients with relapsed multiple myeloma responded to a three-drug regimen including Amgen Inc's Kyprolis than those who got the standard two-drug treatment, according to results from a late-stage trial. Patients with the blood cancer who received the Kyprolis regimen for 18 months also had a longer duration of response and reported better health-related quality of life, data presented on Saturday showed.